shutterstock-126707999-web
Spectral-Design / Shutterstock.com
16 January 2015Asia

Indian Patent Office rejects Sovaldi patent, paves way for generics

The Indian Patent Office (IPO) has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
17 September 2014   US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
Asia-Pacific
26 March 2014   Gilead Sciences has received another challenge to its application to patent its new hepatitis C drug Sovaldi (sofosbuvir) in India.

More on this story

Asia
17 September 2014   US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
Asia-Pacific
26 March 2014   Gilead Sciences has received another challenge to its application to patent its new hepatitis C drug Sovaldi (sofosbuvir) in India.

More on this story

Asia
17 September 2014   US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
Asia-Pacific
26 March 2014   Gilead Sciences has received another challenge to its application to patent its new hepatitis C drug Sovaldi (sofosbuvir) in India.